Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML

Blood Cancer Journal

Volumn 4, Issue 5, 2014, Pages

  Stirewalt, D L ^a   Pogosova Agadjanyan, E L ^a   Tsuchiya, K ^a,b,c   Joaquin, J ^a   Meshinchi, S ^a,b,c,d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; CD34 ANTIGEN; RECOMBINANT DNA; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST CELL; CANCER PATIENT; CANCER PROGNOSIS; CHILD; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA REPAIR; FLT3 GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE LOCUS; GENE MUTATION; GENOTYPE; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; HUMAN CELL; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; ONCOGENE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREVALENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM REPEAT; ACUTE MYELOBLASTIC LEUKEMIA; ALLELE; ENZYMOLOGY; GENETICS; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE;

ALLELES; CHILD; FMS-LIKE TYROSINE KINASE 3; GENOTYPE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LOSS OF HETEROZYGOSITY; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TANDEM REPEAT SEQUENCES;

EID: 84901983839     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.27     Document Type: Article

References (55)

1. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911-1918.
2. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97: 2434-2439.
3. Matsuno N, Nanri T, Kawakita T, Mitsuya H, Asou N. A novel FLT3 activation loop mutation N841K in acute myeloblastic leukemia. Leukemia 2005; 19: 480-481.
4. Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998; 12: 1333-1337.
5. Lavagna-Sevenier C, Marchetto S, Birnbaum D, Rosnet O. FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia 1998; 12: 301-310.
6. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074-3080.
7. Abu-Duhier FM, Goodeve AC, Wilson GA, Gari MA, Peake IR, Rees DC et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000; 111: 190-195.
8. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-1759.
9. Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK et al. Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001; 97: 89-94.
10. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59-66.
11. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335.
12. Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006; 108:3654-3661.
13. Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111: 2776-2784.
14. Schnittger S, Bacher U, Kern W, Alpermann T, Haferlach C, Haferlach T. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia 2011; 25: 1297-1304.
15. Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002; 100: 4372-4380.
16. Griffiths M, Mason J, Rindl M, Akiki S, McMullan D, Stinton V et al. Acquired isodisomy for chromosome 13 is common in AML, and associated with FLT3-itd mutations. Leukemia 2005; 19: 2355-2358.
17. Raghavan M, Lillington DM, Skoulakis S, Debernardi S, Chaplin T, Foot NJ et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res 2005; 65: 375-378.
18. Dunbar AJ, Gondek LP, O'Keefe CL, Makishima H, Rataul MS, Szpurka H et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 2008; 68: 10349-10357.
19. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244-3254.
20. Lange BJ, Dinndorf P, Smith FO, Arndt C, Barnard D, Feig S et al. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941. J Clin Oncol 2004; 22: 150-156.
21. Affymetrix I. CNAT 4.0: Copy Number and Loss of Heterozygosity Estimation Algorithms for the GeneChip® Human Mapping 10/50/100/250/500 K Array Set, 2007 (cited 2013 0716/2013); revision version 1.2:(available from http://www. affymetrix.com/esearch/search.jsp?N=4000097&Ntt=cnat + 4.0&st=doc.
22. Konings P, Vanneste E, Jackmaert S, Ampe M, Verbeke G, Moreau Y et al. Microarray analysis of copy number variation in single cells. Nat Protoc 2012; 7: 281-310.
23. Pollard JA, Alonzo TA, Gerbing RB, Woods WG, Lange BJ, Sweetser DA et al. FLT3 internal tandem duplication in CD34 +/CD33-precursors predicts poor outcome in acute myeloid leukemia. Blood 2006; 108: 2764-2769.
24. Stirewalt DL, Meshinchi S, Kopecky KJ, Fan W, Pogosova-Agadjanyan EL, Engel JH et al. Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes Chromosomes Cancer 2008; 47: 8-20.
25. Ho PA, Kutny MA, Alonzo TA, Gerbing RB, Joaquin J, Raimondi SC et al. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group. Pediatr Blood Cancer 2011; 57: 204-209.
26. Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J et al. Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG. Blood 2011; 118: 4561-4566.
27. Ostronoff F, Othus M, Ho PA, Kutny M, Geraghty DE, Petersdorf SH et al. Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report. Leukemia 2013; 27: 238-241.
28. Brazma A, Parkinson H, Sarkans U, Shojatalab M, Vilo J, Abeygunawardena N et al. ArrayEx press-a public repository for microarray gene expression data at the EBI. Nucleic Acids Res 2003; 31: 68-71.
29. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19: 185-193.
30. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.
31. Stirewalt DL, Choi YE, Sharpless NE, Pogosova-Agadjanyan EL, Cronk MR, Yukawa M et al. Decreased IRF8 expression found in aging hematopoietic progenitor/stem cells. Leukemia 2009; 23: 391-393.
32. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100: 9440-9445.
33. Xu XL, Olson JM, Zhao LP. A regression-based method to identify differentially expressed genes in microarray time course studies and its application in an indu-cible Huntington's disease transgenic model. Hum Mol Genet 2002; 11: 1977-1985.
34. Gene Expression Omnibus (database on the internet), 2007. Available from: http://www.ncbi.nlm.nih.gov/geo/.
35. Ingenuity S. FAQs about statistical considerations, 2006 (cited 2013 7/15/2013). Available from: http://ingenuity.force.com/ipa/IPATutorials?id= kA250000000TNACCA4.
36. Stirewalt DL, Mhyre AJ, Marcondes M, Pogosova-Agadjanyan E, Abbasi N, Radich JP et al. Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS? Br J Haematol 2008; 140: 444-453.
37. Akagi T, Ogawa S, Dugas M, Kawamata N, Yamamoto G, Nannya Y et al. Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype. Haematologica 2009; 94: 213-223.
38. Akagi T, Shih LY, Kato M, Kawamata N, Yamamoto G, Sanada M et al. Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations. Blood 2009; 113: 1741-1748.
39. O'Keefe C, McDevitt MA, Maciejewski JP. Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies. Blood 2010; 115: 2731-2739.
40. Nowak D, Klaumuenzer M, Hanfstein B, Mossner M, Nolte F, Nowak V et al. SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3. Genes Chromosomes Cancer 2012; 51: 756-767.
41. Liehr T. Cytogenetic contribution to uniparental disomy (UPD). Mol Cytogenet 2010; 3: 8.
42. Yi JH, Huh J, Kim HJ, Kim SH, Kim HJ, Kim YK et al. Adverse prognostic impact of abnormal lesions detected by genome-wide single nucleotide polymorphism array-based karyotyping analysis in acute myeloid leukemia with normal karyotype. J Clin Oncol 2011; 29: 4702-4708.
43. Mupo A, Celani L, Dovey O, Cooper JL, Grove C, Rad R et al. A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. Leukemia 2013; 27: 1917-1920.
44. Sistonen L, Keski-Oja J, Ulmanen I, Holtta E, Wikgren BJ, Alitalo K. Dose effects of transfected c-Ha-rasVal 12 oncogene in transformed cell clones. Exp Cell Res 1987; 168: 518-530.
45. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D et al. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 1998; 17: 4657-4667.
46. Araki T, Mohi MG, Ismat FA, Bronson RT, Williams IR, Kutok JL et al. Mouse model of Noonan syndrome reveals cell type-and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 2004; 10: 849-857.
47. Rosenbauer F, Wagner K, Kutok JL, Iwasaki H, Le Beau MM, Okuno Y et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet 2004; 36: 624-630.
48. Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myelo-proliferative disease. J Clin Invest 2004; 113: 528-538.
49. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 2007; 9: 493-505.
50. Wang J, Liu Y, Li Z, Wang Z, Tan LX, Ryu MJ et al. Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose-and cell type-dependent manner. Blood 2011; 118: 368-379.
51. Wang J, Liu Y, Li Z, Du J, Ryu MJ, Taylor PR et al. Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. Blood 2010; 116: 5991-6002.
52. Tuna M, Knuutila S, Mills GB. Uniparental disomy in cancer. Trends Mol Med 2009; 15: 120-128.
53. Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM et al. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood 2004; 104: 2646-2654.
54. Radmacher MD, Marcucci G, Ruppert AS, Mrozek K, Whitman SP, Vardiman JW et al. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood 2006; 108: 1677-1683.
55. Balgobind BV, Van den Heuvel-Eibrink MM, De Menezes RX, Reinhardt D, Hollink IH, Arentsen-Peters ST et al. Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica 2011; 96: 221-230.